Trial · NCT05151016
Long-term Use of Mifepristone in the Treatment of Adenomyosis
NCT05151016, Early phase 1, Unknown, Women's Hospital School Of Medicine Zhejiang University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Long-term Use of Mifepristone in the Treatment of Adenomyosis. Trials, record NCT05151016. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05151016
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Long-term Use of Mifepristone in the Treatment of Adenomyosis
- NCT number
- NCT05151016
- Status
- Unknown
- Phases
- Early phase 1
- Enrollment
- 140 participants, estimated
- Lead sponsor
- Women's Hospital School Of Medicine Zhejiang University
- Conditions
- Adenomyosis, Mifepristone
- Interventions
- mifepristone, Triptorelin Acetate
- First posted
- 2021-12-09
- Last updated
- 2021-12-09
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Pain on the Visual Analogue Scale (VAS) at week 24 | Baseline and Week 24 | The VAS is the most commonly used instrument assessing pain in clinical practice. It reflects the patient's subjective perception of pain. Possible scores range from 0 (no pain) to 10 (worst possible pain). The last observation carry forward was used for missing data. Change=(Week 24 Score - Baseline Score) |
| Secondary | Pictorial blood loss assessment chart（PBAC） | Baseline and week 24 | Recording the use of tampons and sanitary towels by placing a tally mark under the day next to the box. Record clots by indicating whether they are the size of a 1p or 50pcoin in the clots/ flooding row under the relevant day. E.g. under day1 you may say 50p\*1 and 1p\*3. Record any incidences of flooding by placing a tally mark in the clots/ flooding row under the relevant day. A lightly stained towel (pic 1) will score 1 point, a moderately stained towel (pic 2) 5 points, a towel which is saturated with blood(pic 3) will score 20 points. A lightly stained tampon (pic 4) will score 1 point, a moderately stained tampon (pic 5) 5 points and a tampon that is fully saturated will score 10 points. A clot the size of 1p scores 1 point, a 50p sized clot scores 5 pointsand flooding also scores 5 points. Finally, total up the scores. A score of100 or greater may indicate a heavy period. Change=Week 24 Score - Baseline Score |
| Secondary | Change from baseline in uterine size at week 24 | Baseline and week 24 | Uterine size usually reflects the size of the adenomyosis lesion, and is measured in cubic centimeters. Change=(Week 24 Uterine Size - Baseline Uterine Size)\*0.5236 |
| Secondary | Change from baseline in hemoglobin at week 24 | Baseline and week 24 | Hemoglobin, measured in grams per liter, reflects a patient's level of menstrual blood loss. Change=(Week 24 Hemoglobin Content - Baseline Hemoglobin Content) |
| Secondary | Change from baseline in CA125 at week 24 | Baseline and week 24 | CA125 is measured in micrograms per liter. Change=(Week 24 Hemoglobin Content - Baseline Hemoglobin Content) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05151016
GET https://conductscience.org/api/trials/v1/NCT05151016/registered